2021
Financial burden, distress, and toxicity in cardiovascular disease
Slavin SD, Khera R, Zafar SY, Nasir K, Warraich HJ. Financial burden, distress, and toxicity in cardiovascular disease. American Heart Journal 2021, 238: 75-84. PMID: 33961830, DOI: 10.1016/j.ahj.2021.04.011.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesCommunity Health WorkersComparative Effectiveness ResearchDecision Making, SharedFinancial StressHealth Care CostsHealth ExpendituresHumansInsurance CoverageNeeds AssessmentTreatment OutcomeConceptsCardiovascular diseaseFinancial burdenCommunity Health Worker IntegrationHigh-risk individualsComparative effectiveness studiesNon-medical needsHigh-cost interventionsHigh-cost treatmentsCVD managementEffectiveness studiesHealth systemPsychological distressInsurance coverageHealthcare policyBurdenDistressDiseaseSystem navigationInterventionCommunity-based initiativesPatientsPhysicians
2016
Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension A Systematic Review and Network Meta-Analysis
Jain S, Khera R, Girotra S, Badesch D, Wang Z, Murad MH, Blevins A, Schmidt GA, Singh S, Gerke AK. Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension A Systematic Review and Network Meta-Analysis. CHEST Journal 2016, 151: 90-105. PMID: 27615023, PMCID: PMC5310124, DOI: 10.1016/j.chest.2016.08.1461.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntihypertensive AgentsComparative Effectiveness ResearchHumansHypertension, PulmonaryNetwork Meta-AnalysisConceptsPulmonary arterial hypertensionEndothelin receptor antagonistsArterial hypertensionPharmacologic interventionsFunctional statusNew York Heart Association/World Health Organization functional classWorld Health Organization functional classSystematic reviewFuture comparative-effectiveness trialDiscontinuation of therapyA Systematic ReviewComparative effectiveness trialNetwork Meta-AnalysisPatient-centered approachClinical worseningCochrane RegisterSubcutaneous prostanoidsEfficacy outcomesPlacebo groupPlacebo ratesAdverse eventsReceptor antagonistPharmacologic agentsEffectiveness trialComparative efficacy